GMAB Stock Analysis: Genmab AS | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 22.794m USD | 12M Return: 14.4% | US3723032062 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 121M
EPS Trend: 73.7%
Qual. Beats: 0
Rev. Trend: -84.5%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Genmab A/S is a Danish biotechnology company that develops antibody-based therapeutics, primarily for cancer and select other diseases. The company markets several approved products, including EPKINLY/TEPKINLY for relapsed or refractory B-cell lymphomas and Tivdak for recurrent/metastatic cervical cancer. Through partnerships with larger pharmaceutical companies, Genmabs antibody technology also underpins marketed products such as DARZALEX (multiple myeloma), RYBREVANT (NSCLC), TECVAYLI and TALVEY (multiple myeloma), Kesimpta (multiple sclerosis), and TEPEZZA (thyroid eye disease).
The company maintains a broad development pipeline spanning hematologic malignancies, solid tumors, and non-oncology indications, with candidates including Epcoritamab, Tisotumab vedotin, Acasunlimab, Rinatabart Sesutecan, and earlier-stage programs such as GEN1059, GEN1055, GEN1057, and GEN1286. Additional partnered programs include Amivantamab in head and neck and colorectal cancers, Amlenetug for multiple system atrophy, Inclacumab for sickle cell disease, and Mim8 for hemophilia A. As a biotechnology company, Genmab operates a hybrid model that combines in-house discovery and development with commercialization carried out by larger partners.
Genmab has collaboration agreements with major pharmaceutical companies including AbbVie, Pfizer, BioNTech, Johnson & Johnson, Bristol Myers Squibb, Lundbeck, Amgen, Novo Nordisk, and argenx. Founded in 1998 and headquartered in Copenhagen, the company is listed on the NASDAQ under the ticker GMAB and is classified within the Health Care sectors Biotechnology sub-industry. Its business model reflects a common biotech structure in which a smaller innovator generates antibody candidates and earns royalties or profit-sharing revenue from partners that handle late-stage development and global commercialization.
- Royalty revenue from Janssens Darzalex drives cash flow
- Epcoritamab label expansion into frontline lymphoma markets
- Pipeline catalysts for Acasunlimab in NSCLC approach readouts
| Net Income: 788.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA -33.20 > 1.0 |
| NWC/Revenue: 40.21% < 20% (prev 25.21%; Δ 15.00% < -1%) |
| CFO/TA 0.07 > 3% & CFO 890.3m > Net Income 788.1m |
| Net Debt (3.91b) to EBITDA (1.27b): 3.08 < 3 |
| Current Ratio: 2.46 > 1.5 & < 3 |
| Outstanding Shares: last quarter (617.1m) vs 12m ago -0.45% < -2% |
| Gross Margin: 93.03% > 18% (prev 94.83%; Δ -1.80% > 0.5%) |
| Asset Turnover: 43.54% > 50% (prev 201.3%; Δ -157.8% > 0%) |
| Interest Coverage Ratio: 4.36 > 6 (EBIT TTM 1.18b / Interest Expense TTM 269.3m) |
| A: 0.13 (Total Current Assets 2.80b - Total Current Liabilities 1.14b) / Total Assets 12.5b |
| B: 0.35 (Retained Earnings 4.42b / Total Assets 12.5b) |
| C: 0.12 (EBIT TTM 1.18b / Avg Total Assets 9.49b) |
| D: 0.91 (Book Value of Equity 5.96b / Total Liabilities 6.56b) |
| Altman-Z'' = 3.81 = AA |
| DSRI: 3.0 (Receivables 1.28b/997.8m, Revenue 4.13b/13.0b) |
| GMI: 1.02 (GM 94.83% / 93.03%) |
| AQI: 2.15 (AQ_t 0.76 / AQ_t-1 0.35) |
| SGI: 0.32 (Revenue 4.13b / 13.0b) |
| TATA: -0.01 (NI 788.1m - CFO 890.3m) / TA 12.5b) |
| Beneish M = -1.17 (Cap -4..+1) = D |
As of October 13, 2026, the stock is trading at USD 37.37 with a total of 3,126,354 shares traded. Over the past week, the price has changed by -2.88%, over one month by +14.46%, over three months by +29.76% and over the past year by +14.35%.
Current recommended Stop Loss: 35.60 (which is 4.7% or 1.4 ATR below the current price).
Genmab AS has received a consensus analysts rating of 4.75. Therefore, it is recommended to buy GMAB.
- StrongBuy: 10
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 44.1 | 18.1% |
P/E Trailing = 28.5154
P/E Forward = 15.083
P/S = 5.5179
P/B = 3.587
P/EG = 4.3581
Revenue TTM = 4.13b USD
EBIT TTM = 1.18b USD
EBITDA TTM = 1.27b USD
Long Term Debt = 4.84b USD (from longTermDebt, last quarter)
Short Term Debt = 312.0m USD (from shortTermDebt, last quarter)
Debt = 5.41b USD (from shortLongTermDebtTotal, last quarter) + Leases 138.0m
Net Debt = 3.91b USD (calculated: Debt 5.41b - CCE 1.50b)
Enterprise Value = 26.7b USD (22.8b + Debt 5.41b - CCE 1.50b)
Interest Coverage Ratio = 4.36 (Ebit TTM 1.18b / Interest Expense TTM 269.3m)
EV/FCF = 30.79x (Enterprise Value 26.7b / FCF TTM 867.3m)
FCF Yield = 3.25% (FCF TTM 867.3m / Enterprise Value 26.7b)
FCF Margin = 21.00% (FCF TTM 867.3m / Revenue TTM 4.13b)
Net Margin = 19.08% (Net Income TTM 788.1m / Revenue TTM 4.13b)
Gross Margin = 93.03% ((Revenue TTM 4.13b - Cost of Revenue TTM 288.0m) / Revenue TTM)
Gross Margin QoQ = 92.73% (prev 92.75%)
Tobins Q-Ratio = 2.13 (Enterprise Value 26.7b / Total Assets 12.5b)
Interest Expense / Debt = 4.98% (Interest Expense 269.3m / Debt 5.41b)
Taxrate = 13.02% (118.0m / 906.1m)
NOPAT = 1.02b (EBIT 1.18b * (1 - 13.02%))
Current Ratio = 2.46 (Total Current Assets 2.80b / Total Current Liabilities 1.14b)
Debt / Equity = 0.91 (Debt 5.41b / totalStockholderEquity, last quarter 5.96b)
Debt / EBITDA = 3.08 (Net Debt 3.91b / EBITDA 1.27b)
Debt / FCF = 4.51 (Net Debt 3.91b / FCF TTM 867.3m)
Total Stockholder Equity = 5.81b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.31% (Net Income 788.1m / Total Assets 12.5b)
RoE = 13.57% (Net Income TTM 788.1m / Total Stockholder Equity 5.81b)
RoCE = 11.04% (EBIT 1.18b / Capital Employed (Equity 5.81b + L.T.Debt 4.84b))
RoIC = 8.90% (NOPAT 1.02b / Invested Capital 11.5b)
WACC = 7.36% (E(22.8b)/V(28.2b) * Re(8.08%) + D(5.41b)/V(28.2b) * Rd(4.98%) * (1-Tc(0.13)))
Discount Rate = 8.08% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -40.66 | Cagr: -2.72%
[DCF] Terminal Value 73.10% ; FCFF base≈1.56b ; Y1≈1.37b ; Y5≈1.10b
[DCF] Fair Price = 22.46 (EV 17.7b - Net Debt 3.91b = Equity 13.8b / Shares 614.9m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 73.70 | EPS CAGR: 27.60% | SUE: 0.76 | # QB: 0
Revenue Correlation: -84.51 | Revenue CAGR: -42.76% | SUE: -0.83 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.33 | Chg30d=-2.22% | Revisions=+0% | Analysts=6
EPS current Year (2026-12-31): EPS=1.18 | Chg30d=+4.42% | Revisions=+40% | GrowthEPS=-33.4% | GrowthRev=+26.0%
EPS next Year (2027-12-31): EPS=1.52 | Chg30d=-4.09% | Revisions=+0% | GrowthEPS=+29.2% | GrowthRev=+16.9%
[Analyst] Revisions Ratio: +18% (up=5, down=3)